Active Ingredient(s):Macitentan FDA Approved: * October 18, 2013 Pharm Company: *ACTELION PHARMS LTD Category:Blood Pressure
Macitentan, sold under the brand name Opsumit, is an endothelin receptor antagonist (ERA) developed by Actelion and approved for the treatment of pulmonary arterial hypertension (PAH). The other two ERAs marketed as of 2014 are bosentan and ambrisentan. Macitentan is a dual ERA, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ETA and ETB. However, macitentan has a 50-fold increased selectivity for the ETA...
* May have multiple approval dates, manufacturers, or labelers.